Cipla acquires rights to market skin care products of Percos India: Report

03 Sep 2015 Evaluate

Cipla, one of India’s leading generic pharmaceutical companies has reportedly acquired the exclusive rights to market skin care products of Percos India. This deal may be worth an estimated Rs 90 crore. The company will market few fast growing brands like Vedaderm, Claz, Actipeel, Tryses and Glycoveda, which have collective sales of around Rs 10 crore.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For more than 70 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 150 countries. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.

Cipla Share Price

1506.25 14.85 (1.00%)
31-Dec-2025 13:47 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.20
Dr. Reddys Lab 1271.05
Cipla 1506.25
Zydus Lifesciences 913.60
Lupin 2109.20
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×